About The ASCO Post


Mission Statement

Established in 2010, The ASCO Post, in partnership with the American Society of Clinical Oncology (ASCO), communicates news of evidence-based multidisciplinary cancer care to a broad audience of oncology professionals and ASCO members.

It is the #1 oncology newspaper in the field (source: Kantar Media).


The ASCO Post is a newspaper available in print and digitally. Each issue of The ASCO Post features highly validated coverage of clinical cancer research, policy news, patient care, clinical practice issues, and thoughtful commentary by leaders in the field of clinical oncology.

Under the guidance of James O. Armitage, MD, Editor-in-Chief, and a team of more than 40 editorial advisors from the United States and abroad, each issue features highly validated coverage of clinical cancer research and practice issues complemented by thoughtful commentary from leaders in the field of clinical oncology. 

The founding Editor-in-Chief of The ASCO Post, Dr. Armitage is The Joe Shapiro Professor of Medicine in the Division of Oncology & Hematology at the University of Nebraska Medical Center in Omaha. He is a former Dean of the College of Medicine and a past President of ASCO. For more information about the Editorial Board of The ASCO Post, visit


The ASCO Post delivers timely and unbiased reports on major oncology meetings worldwide, including ASCO’s Annual Meeting, and regional and thematic symposia. Additionally, The ASCO Post provides readers with important summaries of evidence-based research from peer-reviewed clinical journals (fully sourced with links to original reports); notable research, data, and literature with application in the clinic, including cost considerations/implications; and columns from ASCO’s membership, with perspective on developments in oncology, quality cancer care, technology, electronic medical records, and expert opinion on the state and economics of cancer care. The ASCO Post publishes news from the National Institutes of Health, the National Cancer Institute, the U.S. Food and Drug Administration, the U.S. Congress, and other governmental agencies; developments in health-care reform and the impact on oncology practice; news from the pharmaceutical and manufacturing industries; information from on clinical trials; issues pertinent to community practice, careers, polls, and oncology trends; meetings calendar; and ASCO member milestones (relocations, new appointments, announcements, etc).


A subscription to The ASCO Post is sent free of charge to approximately 30,000 U.S.-based ASCO members, including oncologists, hematologists, hematologists/oncologists, surgical oncologists, gynecologic oncologists, pediatric oncologists, radiation oncologists, as well as all other domestic nonmember medical oncologists, hematologists, hematologists/oncologists. Additionally, a subscription is also available as a benefit of membership to all U.S.-based ASCO members and Advanced Practitioner Society of Hematology and Oncology (APSHO) nurse practitioners, physician assistants and oncology pharmacists. 

The ASCO Post also publishes The ASCO Post Evening News, a newsletter emailed to 21,550 U.S.-based and 11,000 international ASCO members nightly through the business week. It is a curated digest for health-care providers to quickly and accurately catch up on breaking news in the world of oncology.